Neimeth pharmaceuticals shareholders approve ₦1.99bn capital restructuring scheme transfer
Shareholders of Neimeth International Pharmaceuticals Plc have approved a major capital restructuring scheme that will reduce the company’s share premium account from N2.38 billion to N390.02 million and transfer N1.99 billion to its retained earnings reserve. Nairametrics reported that the approval was granted at a Court-Ordered Meeting held virtually, where shareholders backed up the Scheme […]







